+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bladder Cancer: Epidemiology Forecast to 2028

  • ID: 5006587
  • Report
  • February 2020
  • Region: Global
  • 49 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2
Bladder Cancer: Epidemiology Forecast to 2028

Summary:

The financial burden of diagnosed bladder cancer is expected to grow between 2018 and 2028 in the seven major markets (The US, France, Germany, Italy, Spain, the UK and Japan) due to an increase in disease incident cases from over 225,000 to 275,000, at an annual growth rate (AGR) of 2.21.

Bladder cancer is a common cancer worldwide that occurs when there is uncontrolled cell growth in the bladder lining, most commonly in urothelial cells. The most common risk factor of bladder cancer is tobacco use and cigarette smoking. The risk of bladder cancer also increases with older age, with people ages 65 years and older accounting for 70% of cases. Men are also four times more likely to develop bladder cancer compared with women. Bladder cancer types include carcinoma in situ (CIS), a flat tumor in the inner layer of the bladder that is also referred to as stage Tis.

However, smoking rates have decreased in the 7MM (The US, France, Germany, Italy, Spain, the UK), including in Japan. A more convincing reason for the increase of cases is that the risk of developing bladder cancer increases with age. In the 7MM (The US, France, Germany, Italy, Spain, the UK and Japan) combined, the highest proportion of diagnosed incident cases of bladder cancer in 2018 was among the 70-79 years age group.

The US had the highest number of diagnosed incident and diagnosed prevalent cases of bladder cancer. In 2018, the US had over 76,000 diagnosed incident cases of bladder cancer and the number is expected to increase to more than 96,000 diagnosed incident cases by 2028 at an AGR of 2.58%. The increase in diagnosed incident cases may be due to changes in population and to steadily increasing incidence of bladder cancer in specific age groups. Japan will see the largest increase of cases through the forecast period, at an AGR of 2.99%.
The latest report “Bladder Cancer: Epidemiology Forecast to 2028” provides an overview of the risk factors and global trends of bladder cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of bladder cancer; five-year diagnosed prevalent cases of bladder cancer; diagnosed incident cases of bladder cancer by stage at diagnosis (Ta, Tis, T1, T2, T3, and T4), stage Ta grade, tumor location, stage T4 metastasis, and mutations and biomarkers; and two-year recurrence of diagnosed incident cases of bladder cancer.

Scope:
  • Bladder Cancer Epidemiology Report provides an overview of the risk factors and global trends of bladder cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 7MM: diagnosed incident cases of bladder cancer; five-year diagnosed prevalent cases of bladder cancer; diagnosed incident cases of bladder cancer by stage at diagnosis (Ta, Tis, T1, T2, T3, and T4), stage Ta grade, tumor location, stage T4 metastasis, and mutations and biomarkers; and two-year recurrence of diagnosed incident cases of bladder cancer.
  • The Bladder Cancer Epidemiology Report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy:

The Bladder Cancer Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
  • Quantify patient populations in the global bladder cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for bladder cancer therapeutics in each of the markets covered.
  • Understand magnitude bladder cancer market by stage, mutations and biomarkers.
Note: Product cover images may vary from those shown
2 of 2
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Bladder Cancer: Executive Summary
2.1 Catalysts
2.2 Related Reports
2.3 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors
3.3 Global and Historical Trends
3.3.1 7MM Trends in Diagnosed Incidence
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Bladder Cancer (2018-2028)
3.5.1 Diagnosed Incident Cases of Bladder Cancer
3.5.2 Age-Specific Diagnosed Incident Cases of Bladder Cancer
3.5.3 Sex-Specific Diagnosed Incident Cases of Bladder Cancer
3.5.4 Five-Year Diagnosed Prevalent Cases of Bladder Cancer
3.5.5 Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
3.5.6 Diagnosed Incident Cases of Bladder Cancer by Stage Ta by Grade
3.5.7 Diagnosed Incident Cases of Bladder Cancer by Tumor Location
3.5.8 Diagnosed Incident Cases of Bladder Cancer by Stage T4 Metastasis
3.5.9 Diagnosed Incident Cases of Bladder Cancer with FGFR3 Mutations
3.5.10 Diagnosed Incident Cases of Bladder Cancer (Stages T2, T3, and T4) with PD-L1 Expression
3.5.11 Diagnosed Incident Cases of Bladder Cancer with HER-2 Overexpression
3.5.12 Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About The Publisher
4.4 Contact Us
4.5 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors for Bladder Cancer
Table 4: 7MM, Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018, N

List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018 and 2028, N
Figure 2: 7MM, Diagnosed Prevalent Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018 and 2028, N
Figure 3: 7MM, Diagnosed Incidence of Bladder Cancer, Men, Ages ≥18 Years, 2008-2028, Cases per 100,000 Population
Figure 4: 7MM, Diagnosed Incidence of Bladder Cancer, Women, Ages ≥18 Years, 2008-2028, Cases per 100,000 Population
Figure 5: Sources Used and Not Used for Diagnosed Incident Cases of Bladder Cancer
Figure 6: Sources Used for Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis
Figure 7: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage Ta by Grade
Figure 8: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage by Tumor Location
Figure 9: Sources Used for Diagnosed Incident Cases of Bladder Cancer Stage T4 by Metastasis
Figure 10: Sources Used for Five-Year Diagnosed Prevalent Cases of Bladder Cancer
Figure 11: Sources Used for Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers
Figure 12: Sources Used for Two-Year Recurrence of Diagnosed Incident Cases of Bladder Cancer
Figure 13: 7MM, Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018
Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018, N
Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018, N
Figure 16: 7MM, Five-Year Diagnosed Prevalent Cases of Bladder Cancer, Both Sexes, Ages ≥18 Years, 2018
Figure 17: 7MM, Diagnosed Incident Cases of Bladder Cancer by Stage at Diagnosis, Both Sexes, Ages ≥18 Years, 2018, N
Figure 18: 7MM, Diagnosed Incident Cases of Bladder Cancer Stage Ta by Grade, Both Sexes, Ages ≥18 Years, 2018, N
Figure 19: 7MM, Diagnosed Incident Cases of Bladder Cancer by Tumor Location, Both Sexes, Ages ≥18 Years, 2018, N
Figure 20: 7MM, Diagnosed Incident Cases of Bladder Cancer by Stage T4 Metastasis, Both Sexes, Ages ≥18 Years, 2018, N
Figure 21: 7MM, Diagnosed Incident Cases of Bladder Cancer with FGFR3 Mutations, Both Sexes, Ages ≥18 Years, 2018, N
Figure 22: 7MM, Diagnosed Incident Cases of Bladder Cancer (Stages T2, T3, and T4) with PD-L1 Expression, Both Sexes, Ages ≥18 Years, 2018, N
Figure 23: 7MM, Diagnosed Incident Cases of Bladder Cancer with HER-2 Overexpression, Both Sexes, Ages ≥18 Years, 2018, N
Note: Product cover images may vary from those shown
Adroll
adroll